Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Syndax Pharmaceuticals, Inc. - Common Stock
(NQ:
SNDX
)
21.23
-0.88 (-3.98%)
Streaming Delayed Price
Updated: 2:27 PM EST, Jan 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Syndax Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Syndax and World Orphan Drug Alliance to Launch a Multi-Regional Managed Access Program, Expanding Access to Revuforj® (revumenib) Outside the U.S.
January 07, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
January 05, 2026
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
The Biotech Renaissance: Innovation and M&A Frenzy Spark a Historic Year-End Rally
December 22, 2025
As the curtains draw on 2025, the biotechnology sector has emerged as the undisputed champion of the equity markets, staging a dramatic year-end rally that has caught even the most optimistic analysts...
Via
MarketMinute
Topics
ETFs
Economy
Intellectual Property
Earnings Scheduled For November 3, 2025
↗
November 03, 2025
Via
Benzinga
Syndax Pharmaceuticals's Earnings Outlook
↗
October 31, 2025
Via
Benzinga
Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025
December 12, 2025
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum
December 08, 2025
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 03, 2025
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
SNDX Stock Is The Talk Of The Town Today: Here’s Everything To Know About The Latest FDA Approval
↗
October 24, 2025
Via
Stocktwits
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
December 01, 2025
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 05, 2025
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
↗
November 03, 2025
Via
Benzinga
Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update
November 03, 2025
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025
November 03, 2025
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025
November 03, 2025
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Announces Participation in November Investor Conferences
October 30, 2025
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025
October 27, 2025
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Why Is Syndax Stock Down Today?
↗
October 24, 2025
Shares of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) are trading lower Friday following approval of one of its treatments from the U.S.'s Food and Drug Administration.
Via
Benzinga
Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
October 24, 2025
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Where Syndax Pharmaceuticals Stands With Analysts
↗
October 16, 2025
Via
Benzinga
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 03, 2025
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
September 19, 2025
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
September 05, 2025
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Gains Attention With Strong Drug Portfolio, Path To Leukemia Market Growth
↗
September 04, 2025
Syndax shares gained support after Guggenheim issued a Buy rating, citing strong Q2 results, Revuforj growth, and long-term profit potential.
Via
Benzinga
This HubSpot Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
↗
September 04, 2025
Via
Benzinga
Deep Dive Into Syndax Pharmaceuticals Stock: Analyst Perspectives (5 Ratings)
↗
September 04, 2025
Via
Benzinga
Syndax Announces Participation in September Investor Conferences
August 26, 2025
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 06, 2025
From
Syndax Pharmaceuticals, Inc.
Via
GlobeNewswire
Syndax (SNDX) Q2 Revenue Jumps 986%
↗
August 04, 2025
Via
The Motley Fool
Topics
Intellectual Property
Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Reports Mixed Q2 2025 Earnings with Revenue Beat and Narrower EPS Loss
↗
August 04, 2025
Syndax Pharmaceuticals reported mixed Q2 2025 results, beating revenue estimates with $37.96M but posting an EPS loss of ($0.83). Revuforj sales surged 43%, while shares dipped 3.66% post-earnings.
Via
Chartmill
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit